Helicobacter pylori **VacA-induced Inhibition of GSK3 through** the PI3K/Akt Signaling Pathway^{*}

Received for publication, September 9, 2008, and in revised form, November 3, 2008 Published, JBC Papers in Press, November 7, 2008, DOI 10.1074/jbc.M806981200

Masaaki Nakayama‡ **, Junzo Hisatsune**‡ **, Eiki Yamasaki**§ **, Hajime Isomoto**¶ **, Hisao Kurazono**§ **, Masanori Hatakeyama , Takeshi Azuma******, Yoshio Yamaoka**‡‡**, Kinnosuke Yahiro**§§**, Joel Moss**§§**, and Toshiya Hirayama**‡1

From the ‡ *Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 8528523, Japan, the* § *Department of Applied Veterinary Medicine and Public Health, Obihiro University of Agriculture and Veterinary Medicine, Obihiro 0808555, Japan, the* ¶ *Department of Endoscopy, Nagasaki University School of Medicine, Nagasaki 8528523, Japan, the Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University, Sapporo 0600815, Japan, the* ***Department of Gastroenterology, Kobe University School of Medicine, Kobe 6500017, Japan, the* ‡‡*Department of Medicine-Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, and the* §§*Translational Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892*

Helicobacter pylori **VacA toxin contributes to the pathogenesis and severity of gastric injury. We found that incubation of AZ-521 cells with VacA resulted in phosphorylation of protein kinase B** (Akt) and glycogen synthase kinase- 3β (GSK3 β) through a PI3K**dependent pathway. Following phosphorylation and inhibition of** $GSK3\beta$, β -catenin was released from a $GSK3\beta/\beta$ -catenin complex, with subsequent nuclear translocation. Methyl- β -cyclodextrin **(MCD) and phosphatidylinositol-specific phospholipase C (PI-PLC), but not 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) and bafilomycin A1, inhibited VacA-induced phosphorylation of Akt, indicating that it does not require VacA internalization and is independent of vacuolation. VacA treatment of AZ-521 cells transfected withTOPtkLuciferase reporter plasmid or control FOPtkLucifease reporter plasmid resulted in activation of TOPtk-Luciferase, but not FOPtkLucifease. In addition, VacA transacti**vated the β -catenin-dependent cyclin D1 promoter in a luciferase **reporter assay. Infection of AZ-521 cells by a** *vacA* **mutant strain of** *H. pylori* **failed to induce phosphorylation of Akt and GSK3, or** release of β-catenin from a GSK3β/β-catenin complex. Taken **together, these results support the conclusion that VacA activates the PI3K/Akt signaling pathway, resulting in phosphorylation and** inhibition of $GSK3\beta$, and subsequent translocation of β -catenin to the nucleus, consistent with effects of VacA on β -catenin-regu**lated transcriptional activity.These data introduce the possibility that Wnt-dependent signaling might play a role in the pathogenesis of** *H. pylori* **infection, including the development of gastric cancer.**

Although persistent infection by *Helicobacter pylori* is accepted as a major cause of gastroduodenal diseases, the cellular pathways responsible for the different outcomes such as peptic ulcer disease, gastric lymphoma, or gastric adenocarcinoma have not been defined. Variation in manifestations of *H. pylori* infection in different populations suggest effects of strains differing in virulence, or interactions involving the organism, environmental factor(s), and the host. Many *H. pylori* strains isolated from patients contain the *cagA* gene (cytotoxinassociated gene A) as well as produce the vacuolating cytotoxin, VacA. Additional *H. pylori* products, including urease, OipA, the neutrophil-activating protein NapA, adhesins, heat-shock protein, and lipopolysaccharide, appear to be involved in virulence (1–3).

VacA is a protein toxin with a molecular mass of about 90 kDa, whereas the native toxin is an oligomer of about 1,000 kDa (4). Although a clear functional association between VacA and clinical outcome of any type of gastroduodenal disease has not been found, oral administration of VacA causes gastric mucosal damage in mice (5, 6), suggesting that VacA may contribute to epithelial cell injury or peptic ulceration in *H. pylori*-infected humans.

VacA has multiple effects on susceptible cells, including vacuolation, mitochondrial damage, and inhibition of T cell proliferation (7). These pleiotropic effects of VacA appear to result from activation of different signal transduction pathways. With regard to apoptosis, we have shown that VacA did not directly induce cytochrome *c* release from mitochondria. Rather, VacA stimulated Bax activation, which resulted in cytochrome *c* release and cell death. Although VacA internalization was necessary for vacuolation and Bax activation, VacA-induced Bax activation was independent of vacuole formation, indicating that these activities might be functionally independent (8). In addition, we and others reported that VacA induced alterations in protein phosphorylation patterns, including effects on Erk and p38 mitogen-activated protein kinase $(MAPK)^2$ (9, 10),

² The abbreviations used are: MAPK, mitogen-activated protein kinase; EMEM, Eagle's minimal essential medium; FCS, fetal calf serum; Lef, leukocyte enhancer factor; NaF, sodium fluoride; PBS, phosphate-buffered saline; PVDF, polyvinylidine difluoride; Tcf, T-cell factor; PI3K, phosphatidylinositol 3-kinase; MCD, methyl-β-cyclodextrin; PGE, prostaglandin E; GSK, glycogen synthase kinase; PLC, phospholipase C; NPPB, 5-nitro-2-(3-phenylpropylamino)-benzoic acid.

^{*} This work was supported, in whole or in part, by the Intramural Research Program of the NHLBI, National Institutes of Health (to J. M.). This work was also supported by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in

accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
□ The on-line version of this article (available at http://www.jbc.org) contains

supplemental Figs. [S1–S3.](http://www.jbc.org/cgi/content/full/M806981200/DC1) ¹ To whom correspondence should be addressed:Dept. of Bacteriology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 8528523, Japan. Tel.: 81-95-819-7831; Fax: 81-95-819-7877; E-mail: hirayama@net.nagasaki-u.ac.jp.

which did not require toxin internalization (11) and were not necessary for vacuolation and Bax activation. VacA-dependent MAPK activation, in the absence of toxin internalization, led to induction of COX-2, but not of IL-8, by gastric epithelial AZ-521 cells (9, 12) and expression of IL-8 and monocyte chemoattractant protein-1 (MCP-1) by human promonocytic U937 and peripheral blood mononuclear cells (13). Although the pleiotropic effects of VacA are cell specific, these results suggest that VacA selectively activates kinases (*e.g.* MAPKs), thereby stimulating prostaglandin E_2 (PGE₂) production, facilitating proliferation of AZ-521 cells or chemokine production by U937 cells, and leading to an inflammatory response *in vivo*. Sustained VacA exposure, however, also caused mitochondrial damage and apoptotic cell death. Cells appear to respond to VacA in a manner similar to that seen with stressors (*e.g.* UV irradiation, heat shock, changes in osmolality, oxidative stress, production of inflammatory cytokines) by activating pathways that protect cells from damage. If the stress caused by VacA is excessive, it appears that cells undergo apoptosis.

More recently, it has become evident that glycogen synthase kinase-3 (GSK3) is a crucial, and often central, regulatory component of many cellular pathways, including apoptosis, cell cycle, cell polarity and migration, and gene expression (14). This multitasking by GSK3 is achieved by its phosphorylation of proteins in diverse signal transduction pathways.

Here we report that VacA stimulated protein kinase B (Akt) activity via activation of PI3K, resulting in increased phosphorylation of its substrate, GSK3, with subsequent release of β -catenin from a GSK3 β / β -catenin complex and its translocation to the nucleus, leading to activation of the cyclin D1 promoter. Activation of this $GSK3\beta$ -dependent pathway has been shown to play an important role in promoting pathological changes seen in cancer (15) and appears to be important in the pathogenesis of gastric diseases seen in *H. pylori* infection.

EXPERIMENTAL PROCEDURES

Purification of VacA—The toxin-producing *H. pylori* strain ATCC49503 was the source of VacA for purification by our published procedure (10). In brief, after growth of *H. pylori* in Brucella broth containing 0.1% β -cyclodextrin at 37 °C for 3-4 days with vigorous shaking in a controlled microaerobic atmosphere of 10% O_2 and 10% CO_2 , VacA was precipitated from culture supernatant with 50% saturated ammonium sulfate. Precipitated proteins were dialyzed against Reaction buffer (10 mm KCl, 0.3 mm NaCl, 0.35 mm MgCl₂, 0.125 mm EGTA, 1 mm HEPES, pH 7.3) and applied to an anti-VacA-specific IgG antibody column equilibrated with Reaction buffer. After washing the column with Reaction buffer, VacA was eluted with 50 mm glycine-HCl buffer, pH 1.0, which was promptly neutralized with 1 M Tris-HCl, pH 10. After gel filtration on Superose 6HR 10/30 equilibrated with TBS buffer (60 mm Tris-HCl buffer, pH 7.7, containing 0.1 M NaCl), purified VacA was stored at 20 °C. This purified VacA was activated by acidic elution from an anti-VacA-specific IgG antibody column.

Western Blotting—Human gastric adenocarcinoma cell line AZ-521 (Culture Collection of Health Science Research Resources Bank, Japan Health Sciences Foundation), which were grown in EMEM containing 10% FCS under 5% $CO₂$ at

VacA Inhibition of GSK3 through PI3K/Akt Cascade

37 °C, were incubated with 120 nm VacA at 37 °C for indicated times. After incubation, cell lysates were subjected to SDS-PAGE in 10% gels, and then transferred to PVDF membranes for Western blotting using anti-phospho-Thr-308 Akt, phospho-Ser-473 Akt, phospho-Ser-9 GSK3 β , Akt, or GSK3 β antibodies (products of Cell Signaling). To avoid the enzymatic effects of endogenous phosphatases and proteases during cell lysis, 1 mm Na_3VO_4 and 50 mm NaF were added to block phosphatase activity and 1 mm PMSF and leupeptin (10 μ g/ml) were added to inhibit proteases. Density was measured by scanning using Image J software.

Transfection with PI3K p110 Isoform siRNA—AZ-521 cells $(1 \times 10^5 \, \text{cells})$ were seeded and grown overnight. The cells were transiently transfected with siRNA for PI 3-kinase $p110\alpha$ (200 pmol, the targeting sequence; ggugaaagacgauggacaa, product of B-Bridge International, Inc.) or nonspecific siRNA as a negative control (200 pmol, the sequence; gauaacgaguaaacgggag, product of B-Bridge International, Inc.) by using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA) in medium (500 μ l) without FCS, according to the manufacturer's directions. Following incubation for 5 h, the medium was replaced and fresh medium containing 10% FCS was added, followed by 24-h incubation. Silencing of the $p110\alpha$ gene was determined by measuring $p110\alpha$ protein expression by Western blot analysis using anti-p110 α antibody (Cell Signaling). The transfected cells were incubated with 120 nm VacA at 37 $^{\circ}\mathrm{C}$ for indicated times. After incubation, the cells were lysed. The lysates were subjected to SDS-PAGE in 10% gels, and then transferred to PVDF membranes for Western blot analysis with anti-phospho-Ser-473 Akt, Akt, p110 α , or β -actin antibodies.

Effects of Various Inhibitors on VacA Activation of Akt in AZ-521 Cells—AZ-521 cells were treated with MCD (37 °C, 60 min) or LY294002 (37 °C, 30 min) at indicated concentrations. After treatment with inhibitors, the cells were incubated with 120 nm VacA at 37 °C for 30 min and then lysed. Lysate samples were subjected to SDS-PAGE in 10% gels, transferred to PVDF membranes for Western blotting, and probed with anti-phospho-Ser-473 Akt or Akt antibodies.

Immunoprecipitation of GSK3B/B-Catenin Complex Dissociation-AZ-521 cells were incubated with 120 nm VacA or iVacA for 0 to 240 min. After incubation, cells were solubilized with lysis buffer (50 mm Tris-HCl, pH 7.5, containing 150 mm NaCl, 20% glycerol, 1% Triton X-100, 1μ g/ml leupeptin, 1σ μ g/ml aprotinin, and 1 mm phenylmethylsulfonyl fluoride) and incubated on ice for 30 min. The lysates were analyzed by immunoprecipitation using anti- β -catenin mouse monoclonal antibody (Transduction Laboratories, BD). The precipitates were subjected to SDS-PAGE in 9% gels and transferred to PVDF membranes. Next, $GSK3\beta$ and β -catenin were quantified by Western blot analysis using anti- $GSK3\beta$ rabbit monoclonal antibodies (rabbit monoclonal antibody 27C10, product of Cell Signaling), and anti- β -catenin rabbit polyclonal antibody (1:1,000; H-102, product by Santa Cruz Biotechnology), respectively. These experiments were repeated three times.

-Catenin Translocation from Cytosol to Nucleus—AZ-521 cells were incubated with 120 nm VacA or iVacA for 0, 30, and 60 min. After incubation, the cells were fixed at room temperature for 10 min in PBS containing 2% paraformaldehyde. The

FIGURE 1. VacA-induced Akt phosphorylation leading to GSK3 β phosphorylation at Ser9. A, AZ-521 cells were incubated with 120 nm VacA or heat-inactivated VacA (*iVacA*) at 37 °C for the indicated times. After incubation, cell lysates were analyzed by SDS-PAGE (10% gels), followed by Western blot analyses using anti-phospho-Thr-308 Akt, phospho-Ser-473 Akt, and Akt antibodies. Results are representative of three independent experiments. Quantification of phospho-Thr-308 Akt and phospho-Ser-473 Akt obtained with VacA (*filled bars*) and iVacA (*open bars*) was performed by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: *, p < 0.01. *B*, AZ-521 cells were incubated with 120 nM VacA (*filled bars*) or iVacA (*open bars*) at 37 °C for indicated times. Cell lysates were prepared at indicated incubation times and subjected to Western blot analyses using anti-phospho-Ser-9 GSK3 β and GSK3 β antibodies. Results are representative of three independent experiments. Quantification of phospho-Ser-9 GSK3 obtained with VacA (*filled bars*) and iVacA (*open bars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: $*, p < 0.05$.

fixed cells were treated for 5 min with 0.1% Triton X-100 for membrane permeabilization and blocked with 4% Block Ace (in PBS, Snow Brand Milk Products, Tokyo, Japan) for 30 min. The fixed cells were studied by triple-immunostaining using anti- β catenin mouse monoclonal antibodies (Transduction Laboratories, BD) and anti-GSK3 β rabbit monoclonal antibodies (Cell Signaling) as primary antibodies in TBS containing 1% bovine serum albumin (BSA). After treatment with the respective primary antibodies, cells were incubated with secondary antibodies in TBS containing 1% BSA, utilizing anti-mouse antibodies conjugated with Alexa Fluor 488 or anti-rabbit antibodies conjugated with Alexa Fluor 546, respectively. The samples were analyzed with confocal microscopy using Leica Confocal Scanning System.

Luciferase Reporter Assay—Luciferase activity was measured using the Dual-Luciferase reporter assay (product of Promega), according to the manufacturer's directions. TOPtkLuciferase and FOPtkLuciferase reporter constructs carrying 3 copies of

(A)

FIGURE 2. **Effect of various inhibitors on VacA-induced phosphorylation of AktinAZ-521 cells.**AZ-521 cellswerepretreatedwithLY294002for 30min(*A*) or MCD for 60 min (*B*) at the indicated concentrations prior to incubation with or without 120 nm VacA. After incubation for 30 min, cell lysates were prepared and subjected to Western blot analyses using anti-phospho-Ser-473 Akt and Akt antibodies. Results are representative of three independent experiments. Quantification of phospho-Ser-473 Akt obtained with (*filled bars*) or without VacA (*open bars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n=3$ per experiment. Statistical significance: $*$, $p<$ 0.05.

FIGURE 3. **Effect of PI-PLC, NPPB, or Bafilomycin A1 on VacA-induced Akt phosphorylation in AZ-521 cells.** AZ-521 cells were pretreated with PI-PLC (1 unit/ml, 60 min), NPPB (50 μ m, 30 min), or Bafilomycin A1 (5 nm, 30 min) at the indicated concentrations. After treatment, the cells were incubated with 120 nm VacA or iVacA at 37 °C for 30 and 60 min. Following incubation, the cell lysates were subjected to SDS-PAGE in 10% gels and transferred to PVDF membranes for Western blotting with anti-phospho-Ser-473 Akt and Akt antibodies. Quantificationofphospho-Ser-473AktobtainedwithVacA(*filledbars*)andiVacA(*openbars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: *, $p < 0.05$.

wild-type Tcf/Lef-binding sites and mutated Tcf/Lef-binding sites, respectively, were placed upstream of a luciferase reporter gene (16, 17). In brief, TOPtkLuciferase plasmids (1 μ g), FOPtk-

FIGURE 4. **Effect of PI3K p110** α **siRNA on VacA-induced Akt phosphorylation and effects of LY294002 and silencing of the** *PI3K* **gene on VacA-induced phosphorylation at Ser-9 of GSK3.** *A*, AZ-521 cells were transiently transfected with siRNA for PI3K p110 α or negative siRNA as a control as described under "Experimental Procedures." The transfected cells were incubated with 120 nm VacA at 37 °C for up to 60 min. After incubation, cell lysates were subjected to SDS-PAGE in 10% gels, and then transferred to PVDF membranes for Western blot analysis with the antibodies against phospho-Ser-473 Akt, Akt, and PI3K p110 α . Quantification of phospho-Ser-473 Akt obtained with VacA (*filled bars*) and iVacA (*open bars*) was determined by densitometry scan analysis. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: $*, p < 0.05$. *B*, AZ-521 cells were pretreated with 50 μ M LY294002 for 30 min before incubation with 120 nm VacA or iVacA at 37 °C. After incubation with VacA or iVacA for indicated times, the cell lysates were applied to SDS-PAGE in 10% gels. The separated proteins were transferred to PVDF membranes, and subjected to Western blot analysis with anti-phospho-Ser-9 GSK3 β and GSK3 β antibodies. Quantification of phospho-Ser-9 GSK3 was determined by densitometry for VacA (*filled bars*) and iVacA (*open bars*). Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: *, p < 0.05. C, AZ-521 cells were transiently transfected with 200 pmol of siRNA for PI3K p110 α or negative siRNA as negative control as described under "Experimental Procedures." The transfected cells were incubated with 120 nm VacA or iVacA at 37 °C for indicated times. After incubation, the cell lysates were subjected to SDS-PAGE in 10% gels, and then transferred to PVDF membranes for Western blot analysis with anti-phospho-Ser-9 GSK3 β , GSK3 β , and PI3K p110 α antibodies. Quantification of phospho-Ser-9 GSK3 β obtained with VacA (*filled bars*) and iVacA (*open bars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: *, $p < 0.05$.

Luciferase plasmids (1 μg), *Cyclin D1*Luciferase plasmids (1 μ g), or pRL-TK vector plasmids (0.1 μ g) was introduced into AZ-521 cells using Transfast transfection reagents (product of Promega) as described previously (18). The cells were incubated with EMEM containing 10% FCS for 12 h. After transfection with plasmid, the medium was replaced with new medium without FCS and then incubated for 24 h. After AZ-521 cells were treated with VacA for the indicated times, cells were washed with 500 μ l of PBS and lysed by adding 100 μ l of lysis buffer (Promega). After incubation for 15 min at room temperature, the lysate was centrifuged (15,000 \times *g*, 5 min, 4 °C), and the supernatant was harvested and assayed with LAR II solution, which was provided a substrate for Firefly luciferase or with Stop and Glo solution, which was provided a substrate for *Renilla* luciferase. Luciferase activity was normalized to the pRL-TK luciferase activity.

Infection of AZ-521 Cells with H. pylori—*H. pylori* standard strain ATCC43504 and its *vacA* mutant strain were used. VacA mutants were constructed as previously described (19) with the exception that we used a kanamycin resistance gene cassette in this study. Before challenging AZ-521 cells, *H. pylori* strains were cultured in Brucella broth supplemented with 5% FCS under microaerobic conditions for 12–24 h at 37 °C with vigorous shaking, and then incubated with AZ-521 cells $(5 \times 10^5$ cells) at a multiplicity of infection (MOI) of 100 for 6 h. After incubation in a 5% $CO₂$ atmosphere for the time indicated in each figure, phosphorylation of Akt and $GSK3\beta$ in infected cells was determined by Western blotting. Dissociation of $GSK3\beta/\beta$ -catenin complex was assessed by quantification of $GSK3\beta$ and β -catenin by Western blotting after immunoprecipitation of *H. pylori*-infected cell lysates using anti- β -catenin mouse monoclonal antibody.

Statistical Analysis—To establish the significance of the results, the Student's *t* test was used for numerical data. Fisher's exact test or χ^2 test was used for categorical data as appropriate. A *p* value less than 0.05 was considered statistically significant.

RESULTS

VacA Activation of Akt and Subsequent GSK3 Phosphorylation— The PI3K/Akt signaling pathway, activated in response to insulin and many other growth factors, often is

a major regulator of GSK3 through phosphorylation by Akt of an inhibitory serine residue (20). To determine whether VacA induces Akt phosphorylation, AZ-521 cells were incubated with 120 nm VacA. We observed that VacA stimulated phosphorylation of Akt at regulatory residues Thr-308 and Ser-473, consistent with activation of Akt activity (Fig. 1*A*). Cells incubated with heat-inactivated VacA showed low or undetectable levels of Akt phosphorylation. Phosphorylation of both Thr-308 and Ser-473 was clearly evident within a 60-min incubation with VacA and declined thereafter. Addition of anti-VacA IgG blocked VacA-stimulated Akt phosphorylation (data not shown), suggesting that Akt phosphorylation and subsequent effects were not due to the presence of contaminants in the purified VacA (*e.g.* endotoxin). In rat fibroblast-like synoviocytes and human skin fibroblasts, Akt has been shown to participate in signaling pathways that lead to translocation of $NF-\kappa B$ to the nucleus and increased $NF-\kappa B$ -dependent transcription (21). In AZ-521 cells, however, we found that VacA

did not enhance nuclear translocation of NF - κ B (supplemental Fig. [S1\)](http://www.jbc.org/cgi/content/full/M806981200/DC1). In contrast, the increase in phosphorylation of another potential downstream substrate, $GSK3\beta$, at Ser-9 paralleled the rise in phosphorylation of Thr-308 and Ser-473 and was maximal at 30– 60 min and declined within 120 min (Fig. 1*B*), suggesting that VacA may cause phosphorylation and inhibition of $GSK3\beta$ activity by Akt activation.

Effects of LY294002 and MCD on VacA Activation of Akt Phosphorylation—In the presence of PI3K inhibitor LY294002, VacA-treated cells and control cells showed equivalent and reduced levels of Akt phosphorylation at Ser-473 (Fig. 2*A*), demonstrating that blocking PI3K activity pharmacologically resulted in inhibition of both basal phosphorylation of Akt as well as VacA activation of Akt. To define further the mechanism by which PI3K activity regulates Akt phosphorylation, we asked whether the inhibitory effect of LY294002 could be reproduced with an inhibitor of VacA cellular effects. Blocking VacA clustering in lipid rafts with MCD, a cholesterol-depleting reagent which disrupts lipid rafts, inhibited VacA-induced Akt activation in AZ-521 cells (Fig. 2*B*). Taken together, these data identify lipid rafts and the PI3K/Akt pathway as participating in VacA inhibition of GSK3 β in AZ-521 cells.

Effects of 5-Nitro-2-(3-phenylpropylamino)-benzoic Acid (NPPB), Bafilomycin A1, and Phosphatidylinositol-specific Phospholipase C (PI-PLC) on VacA Activation of Akt Phosphorylation—In addition to MCD, it is well known that NPPB (22), which disrupts anion channels, or bafilomycin A1 (23), which is a vacuolar-type H^+ ATPase inhibitor, inhibited VacA internalization followed by vacuolation. In addition, PI-PLC, which cleaves the glycolipid of GPI-anchored proteins, inhibited VacA translocation to lipid rafts, VacA internalization, and VacA-induced vacuolation (11, 24). Consistent with inhibition of VacA effects by MCD, PI-PLC inhibited VacA-induced Akt phosphorylation, whereas NPPB and bafilomycin A1 had no inhibitory effect (Fig. 3). These results support our hypothesis that Akt phosphorylation induced by VacA requires VacA translocation to lipid rafts, but does not require VacA internalization or vacuolation.

Inhibition of VacA Activation of Akt Phosphorylation and GSK3 Phosphorylation by PI3K p110 Isoform Silencing and PI3K Inhibitor—To address whether PI3K is crucial for VacA stimulation of Akt phosphorylation, AZ-521 cells were transfected with PI3K p110 α siRNA. Reduced p110 α expression in AZ-521 cells, treated with $p110\alpha$ -siRNA, resulted in suppression of Akt phosphorylation in response to VacA (Fig. 4*A*). To characterize further the mechanism by which PI3K activity regulates $GSK3\beta$ phosphorylation, we examined whether the inhibitory effects of LY294002 and PI3K $p110\alpha$ silencing reduced VacA activation of $GSK3\beta$ phosphorylation. Both LY294002 and PI3K p110 α silencing blocked VacA-induced $GSK3\beta$ phosphorylation in AZ-521 cells, suggesting that PI3K activation is critical for GSK3 β phosphorylation (Fig. 4, *B* and *C*).

VacA Induces Dissociation of the GSK3/-Catenin Complex—GSK3 β is one of the key elements of the Wnt pathway, which governs β -catenin homeostasis. Inhibition of GSK3

FIGURE 5.**GSK3/-catenin complexes are dissociated by VacA in AZ-521 cells.** AZ-521 cells were incubated with 120 nm VacA or iVacA for 0-240 min in the presence or absence of 50 μ m LY294002. After incubation, the cells were solubilized with lysis buffer and incubated on ice for 30 min. The lysates were available for immunoprecipitation using anti- β -catenin mouse monoclonal antibody (Transduction Laboratories, BD). The precipitates were subjected to SDS-PAGE in 8% gels and transferred to PVDF membranes. Then, GSK3 β and β -catenin were quantified by Western blot analysis using anti-GSK3 β rabbit monoclonal antibody (1:1,000; Cell Signaling) and anti- β -catenin rabbit polyclonal antibody (1:1,000; H-102, Santa Cruz Biotechnology), respectively. Quantification of phospho-Ser-9 GSK3 obtained with VacA (*filled bars*) and iVacA (*open bars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: $\frac{*}{p}$ < 0.01.

kinase activity might lead to stabilization of β -catenin and upregulation of Lef-1/Tcf family of transcription factors, representing a potential mitogenic stimulus (25, 26). Wnt treatment disassembles the $Axin/GSK3\beta$ complex, thus decreasing $GSK3\beta$ phosphorylation of both β -catenin and Axin. Whereas unphosphorylated β -catenin is stabilized, unphosphorylated Axin is subject to proteasomal degradation, further reducing $Axin/GSK3B$ complex levels (14, 27, 28). Therefore, we next assessed whether VacA induces dissociation of $GSK3\beta$ and β -catenin from a GSK3 β / β -catenin complex in AZ-521 cells. Western blot presents data compatible with dissociation of GSK3 β and β -catenin from a GSK3 β/β -catenin complex in AZ-521 cells incubated with VacA (Fig. 5). Blocking VacA-induced dissociation of $GSK3\beta/\beta$ -catenin complex with LY294002 suggests the involvement of PI3K/Akt pathway in this process.

VacA Induced β-Catenin Translocation to Nucleus-VacA induced translocation of β -catenin to the nucleus as visualized by immunostaining with anti- β -catenin antibody (Fig. 6*A*), whereas heat-inactivated VacA did not cause β -catenin translocation (Fig. 6*B*).

-Catenin-dependent Gene Transcription—To demonstrate the activation of β -catenin-dependent gene transcription by VacA, we examined the effect of VacA on β -catenin-dependent transcriptional activity of AZ-521 cells transfected with TOPtkLuciferase reporter plasmid or control FOPtk-Luciferase reporter plasmid.VacAinduced activation ofTOPtk-Luciferase, but not FOPtkLucifease (Fig. 7, *A* and *B*). In addition, VacA also transactivated the β -catenin-dependent cyclin D1 promoter in a luciferase reporter assay, suggesting that VacA stimulates β -catenin signaling, which is one of the major signal transduction pathway involved in development of gastric cancer and in the induction of cyclin D1 expression (Fig. 7*C*).

FIGURE 6. **Confocal microscopy analysis of** β **-catenin translocation to nucleus from cytosol.** AZ-521 cells were incubated with 120 nm VacA (A) or iVacA (*B*) at 37 °C for 0, 30 and 60 min. After incubation, the cells were fixed using 2% paraformaldehyde at room temperature, treated with 0.1% Triton X-100, and blocked with Block Ace. The fixed cells were stained with DAPI for 5 min, and were subjected to triple immunostaining using anti- β -catenin monoclonal antibodies and anti- $GSK3\beta$ monoclonal antibodies as primary antibodies. After treatment with the respective primary antibodies, cells were incubated with the secondary anti-mouse antibodies, conjugated with Alexa Fluor 488, and anti-rabbit antibodies conjugated with Alexa Fluor 546, respectively. Data are representative of three experiments. *Scale bar*, 5 μ m.

Phosphorylation of Akt and GSK3 in AZ-521 Cells Infected with H. pylori Strain Containing a VacA Gene—To determine whether production of VacA by *H. pylori* induces phosphorylation of Akt and GSK3 β , AZ-521 cells were infected with *H. pylori* ATCC43504 (WT strain) or its isogenic VacA knock-out mutant strain (Δ VacA strain). After challenging AZ-521 cells with WT strain, greater phosphorylation of Akt at Ser-473 and GSK3 β at Ser-9 was observed, with dissociation of β -catenin from the GSK3 β/β -catenin complex, whereas a Δ VacA strain did not have similar effects, implying that VacA production by *H. pylori* is responsible for Akt activation leading to GSK3 β phosphorylation (Fig. 8).

DISCUSSION

VacA enhances PGE₂ production by AZ-521 cells through induction of COX-2 expression via the p38 MAP kinase/ATF-2 cascade without any effect on the *COX-2* gene promoter at its $NF-\kappa B$ site (12). Consistent with previous findings, in AZ-521 cells, VacA did not affect intracellular Ca^{2+} -release and NF- κ B translocation to the nucleus (supplemental Fig. [S1\)](http://www.jbc.org/cgi/content/full/M806981200/DC1) despite the fact that in U937 cells, VacA increased IL-8 production by activation of the p38 MAP kinase via intracellular Ca^{2+} -release, leading to activation of the transcription factors, ATF-2, CREB, as well as NF-KB (13). In addition, VacA initiated an intracellular signaling pathway, leading to the inactivation of NF-AT in Jurkat T cells by blocking increases in intracellular Ca^{2+} . Thus, it appears that effects of VacA on these transcription factors can be cell type-specific and regulated through different mechanisms.

Because it is well known that PI3K and Akt participate in signaling pathways induced by endotoxin that lead to $NF - \kappa B$ activation (29), we examined whether, in AZ-521 cells, VacA affects Akt phosphorylation and found that VacA stimulated phosphorylation of Akt as well as its downstream substrate $GSK3\beta$ (Fig. 1), but did not stimulate NF- κ B activation. In agreement, pharmacologic studies using LY294002 and PI3K $p110\alpha$ silencing blocked VacA-induced GSK3 β phosphoryl-

FIGURE 7. Effect of VacA on β -catenin-Tcf-mediated transcription and cyclin D1 promoter activity. AZ-521 cells were transfected with the luciferase reporter plasmid TOPtkLuciferase (*filled bars*) or FOPtkLuciferase (open bars), and internal control pRL-TK, followed by incubation with 120 nm VacA (A) or iVacA (B) for indicated times. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System. Relative luciferase activities were compared with activities obtained for TOPtkLuciferase at 0 min in the presence of toxin. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: $*, p < 0.01$. *C*, AZ-521 cells were transfected with a reporter plasmid containing the cyclin D1 promoter-luciferase gene or a control empty vector. After transfection, cells were incubated with VacA (*filled bars*) or iVacA (*open bars*). Relative luciferase activities were compared with activities obtained at 0 min in the presence of iVacA. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: $*, p < 0.01$.

ation in AZ-521 cells, suggesting that VacA stimulated phosphorylation of Akt and $GSK3\beta$ through PI3K-dependent pathways (Fig. 4). VacA induced changes in protein phosphorylation, including Erk and p38 MAPKs (9, 10), which did not require toxin internalization (11). VacA-induced phosphorylation of Akt and $GSK3\beta$ through PI3K-dependent pathways may not be due to Erk and p38 MAPKs because it was not blocked by a specific inhibitor of p38 MAP kinase activity, SB203580, and with a MEK inhibitor, PD98059, which is known to block the Erk1/2 signal cascade (supplemental Fig. [S2\)](http://www.jbc.org/cgi/content/full/M806981200/DC1). Although MCD and PI-PLC were inhibitory, NPPB and bafilomycin A1 had no effect

FIGURE 8. **Phosphorylation of Akt and GSK3 and dissociation of GSK3/ -catenin complexes in AZ-521 cells infected with** *H. pylori***, but not an isogenic VacA-knock-out mutant strain.** AZ-521 cells were infected for 6 h with *H. pylori* ATCC43504 (*WT strain*) or its isogenic VacA-knock-out mutant strain (*VacA strain*). Cells incubated without infection (uninfected cells) were used as a negative control. *A*, after incubation, phosphorylation of Akt and $GSK3\beta$ in cells was determined by Western blot analysis with anti-phospho-Ser-473 Akt, Akt phospho-Ser-9 GSK3 β , and GSK3 β antibodies. Quantification of phospho-Ser-473 Akt and phospho-Ser-9 GSK3 β obtained with control (*open bars*), *WT strain* (*black bars*), and *VacA strain* (*gray bars*) was determined by densitometry. Data are means \pm S.E. of values from triplicate experiments, with an $n = 3$ per experiment. Statistical significance: *, $p < 0.05$. *B*, after incubation, proteins from cell lysates were immunoprecipitated using anti- β -catenin antibody, followed by SDS-PAGE in 8% gels and Western blotting with anti- β -catenin and GSK3 β antibodies. Relative densities of GSK3 β , as determined by densitometry, were compared with densities obtained at 0 min. Data are means \pm S.E. of values from triplicate experiments, with an $n =$ 3 per experiment. Statistical significance: *, $p < 0.05$.

on VacA-induced phosphorylation of Akt (Fig. 3), indicating that VacA-induced signaling pathways leading to Akt phosphorylation do not require VacA internalization and are independent of vacuolation caused by VacA (8), as is VacAinduced p38 MAP kinase activation (11). It has been reported that ammonium chloride enhances several cellular effects of VacA, with the most notable being the potentiation of cellular vacuolation because it might be possible to detect subtle effects of VacA on endocytic processes that are obscured by the extensive changes in cellular architecture associated with VacA-induced vacuolation (30). Although ammonium chloride (5 mm) stimulated VacA-induced vacuolation in AZ-521 cells about 2-fold at 60 min of incubation under our experimental condition, it did not affect phosphorylation of Akt and $GSK3\beta$ (supplemental Fig. [S3\)](http://www.jbc.org/cgi/content/full/M806981200/DC1).

Infection of AZ-521 cells with a *vacA* mutant strain of *H*. *pylori* failed to induce Akt phosphorylation (Fig. 8), suggesting

FIGURE 9. **VacA or an** *H. pylori vacA-***positive strain induced activation of** PI3K p110 α /Akt pathway leading to inactivation of GSK3 β and **enhanced transcriptional activity of β-catenin.** VacA or an *H. pylori vacA*positive strain activated the PI3K/Akt signaling pathway, resulting in phosphorylation and inhibition of GSK3 β , and subsequent translocation of β -catenin to the nucleus, consistent with effects of VacA on β -catenin-regulated transcriptional activity.

that VacA is responsible for activation of the PI3K/Akt pathway. Thus, the finding that VacA-induced activation of PI3K/ Akt pathway negatively regulates $GSK3\beta$ function is also reasonable because it has been reported that $GSK3\beta$ is necessary for the full transcriptional activity of NF - κ B (31), although the inhibition of $GSK3\beta$ may not interfere with all actions of NF - κ B. In agreement, in AZ-521 cells treated with VacA, nuclear translocation of NF-KB did not differ from non-treated control cells (Fig. [S1\)](http://www.jbc.org/cgi/content/full/M806981200/DC1).

 $GSK3\beta$ does not have specific subcellular localization motifs, but various extracellular signals can impact the interaction of GSK3 with its target substrates. Canonical Wnt signaling functions primarily by regulating $GSK3\beta$ to promote the rapid, cytosolic accumulation of the multifunctional protein β -catenin. In quiescent cells, β -catenin is principally found in association with cytoskeletal components (*e*.*g*. E-cadherin), where it functions to orchestrate actin dynamics and regulate cell adhesion, cell-cell interactions, and intercellular communication. In addition to its role as a cytoskeletal component, β -catenin can also function as a transcriptional co-factor; complexes of β -catenin and Lef/Tcf transcription factors serve as nuclear activators (32) of gene sets that promote specific developmental pathways or tumorigenesis (28). Confocal microscope visualization with anti- β -catenin antibody revealed that VacA induced translocation of β -catenin to the nucleus (Fig. 6), suggesting that PI3K/Akt-dependent pathways induced by VacA stimulate $GSK3\beta$ phosphorylation and thus promote the accumulation of an uncomplexed, cytosolic population of β -catenin (Fig. 5) that may be available for interaction with and activation of Lef/Tcf family members after its nuclear translocation (Fig. 9).

Indomethacin, which is an inhibitor of COX, reducing its production of prostanoids, significantly delayed epithelial regeneration *in vivo* (33). In contrast to the action of indomethacin, VacA induced COX-2 expression, resulting in enhancement of $PGE₂$ production in AZ-521 cells during early VacA action (12), even though VacA eventually is responsible for gastric injury through induction of cell detachment from basal membrane and apoptosis after longer exposure to toxin.

Although the involvement of the $COX-2/PGE_2$ pathway in the regulation of cell survival and death by VacA remains controversial, here, we found that the increasing incubation times with VacA dramatically increased both the phosphorylation of Akt and GSK3 β , suggesting that the PI3K/Akt pathway was necessary for inhibition of $GSK3\beta$ function during early VacA action. Indeed, its inhibition was sufficient to dissociate a $GSK3\beta/\beta$ -catenin complex during 2 h incubation with VacA. However, longer exposure (over 4 h) with VacA resulted in increased $GSK3\beta/\beta$ -catenin complex levels compared with a short exposure for 2 h (Fig. 5). At that time, Akt was no longer active, which resulted in a decrease in the inhibition of phosphorylation of GSK3 β on Ser-9 and hence, in a higher GSK3 β activity. GSK3 inhibition reverted the prolonged activation of transcriptional function of β -catenin; after prolonged exposure to VacA, more β -catenin was observed in the nucleus compared with a short exposure, consistent with increased β -catenin transcriptional activity, which may contribute expression of a growth-promoting protein such as cyclin D1 (Fig. 7) (34). Interestingly, it has been reported that the activation of the Wnt/β -catenin signaling is found in about 30% of gastric cancer (35), suggesting that Wnt activation may be involved in the pathogenesis of gastric cancer. Consistent with this finding, Oshima *et al.* (36) recently showed that cooperation of Wnt signaling and PGE_{2} -dependent pathways results in gastric cancer in a transgenic mouse model.

In conclusion, VacA induced two effects on β -catenin, with activation and nuclear accumulation following a short incubation, which depends on an active PI3K/Akt pathway and an inactive $GSK3\beta$, whereas prolonged incubation with VacA results in inactivation of Akt and activation of $GSK3\beta$, which then down-regulates β -catenin activity.

Acknowledgments—We thank K. Maeda, K. Tamura, and K. Shiraishi for skillful assistance, and I. Kato (Chiba University School of Medicine) for helpful discussions. We thank M. Vaughan of the Translational Medicine Branch, NHLBI, National Institutes of Health (Bethesda, MD) for helpful discussions and critical review of the manuscript.

REFERENCES

- 1. Atherton, J. C. (2006) *Annu. Rev. Pathol.* **1,** 63–96
- 2. Kusters, J. G., van Vliet, A. H., and Kuipers, E. J. (2006)*Clin. Microbiol. Rev.* **19,** 449–490
- 3. D'Elios, M. M., Montecucco, C., and de Bernard, M. (2007) *Clin. Chim. Acta* **381,** 32–38
- 4. Manetti, R., Massari, P., Burroni, D., de Bernard, M., Marchini, A., Olivieri, R., Papini, E., Montecucco, C., Rappuoli, R., and Telford, J. L. (1995) *Infect. Immun.* **63,** 4476–4480
- 5. Telford, J. L., Ghiara, P., Dell'Orco, M., Comanducci, M., Burroni, D., Bugnoli, M., Tecce, M. F., Censini, S., Covacci, A., Xiang, Z. Y., Papini, E., Montecucco, C., Parente, L., and Rappuoli, R. (1994) *J. Exp. Med.* **179,** 1653–1658
- 6. Fujikawa, A., Shirasaka, D., Yamamoto, S., Ota, H., Yahiro, K., Fukuda, M., Shintani, T., Wada, A., Aoyama, N., Hirayama, T., Fukamachi, H., and Noda, M. (2003) *Nat. Genet.* **33,** 375–381
- 7. Cover, T. L., and Blanke, S. R. (2005) *Nat. Rev. Microbiol.* **3,** 320–332
- 8. Yamasaki, E., Wada, A., Kumatori, A., Nakagawa, I., Funao, J., Nakayama, M., Hisatsune, J., Kimura, M., Moss, J., and Hirayama, T. (2006) *J. Biol.*

VacA Inhibition of GSK3 through PI3K/Akt Cascade

Chem. **281,** 11250–11259

- 9. Boncristiano, M., Paccani, S. R., Barone, S., Ulivieri, C., Patrussi, L., Ilver, D., Amedei, A., D'Elios, M. M., Telford, J. L., and Baldari, C. T. (2003) *J. Exp. Med.* **198,** 1887–1897
- 10. Nakayama, M., Kimura, M., Wada, A., Yahiro, K., Ogushi, K., Niidome, T., Fujikawa, A., Shirasaka, D., Aoyama, N., Kurazono, H., Noda, M., Moss, J., and Hirayama, T. (2004) *J. Biol. Chem.* **279,** 7024–7028
- 11. Nakayama, M., Hisatsune, J., Yamasaki, E., Nishi, Y., Wada, A., Kurazono, H., Sap, J., Yahiro, K., Moss, J., and Hirayama, T. (2006) *Infect. Immun.* **74,** 6571–6580
- 12. Hisatsune, J., Yamasaki, E., Nakayama, M., Shirasaka, D., Kurazono, H., Katagata, Y., Inoue, H., Han, J., Sap, J., Yahiro, K., Moss, J., and Hirayama, T. (2007) *Infect. Immun.* **75,** 4472–4481
- 13. Hisatsune, J., Nakayama, M., Isomoto, H., Kurazono, H., Mukaida, N., Mukhopadhyay, A. K., Azuma, T., Yamaoka, Y., Sap, J., Yamasaki, E., Yahiro, K., Moss, J., and Hirayama, T. (2008) *J. Immunol.* **180,** 5017–5027
- 14. Kim, L., and Kimmel, A. R. (2006) *Curr. Drug Targets.* **7,** 1411–1419
- 15. Giles, R. H., van Es, J. H., and Clevers, H. (2003) *Biochim. Biophys. Acta* **1653,** 1–2
- 16. Tago, K., Nakamura, T., Nishita, M., Hyodo, J., Nagai, S., Murata, Y., Adachi, S., Ohwada, S., Morishita, Y., Shibuya, H., and Akiyama, T. (2000) *Genes Dev.* **14,** 1741–1749
- 17. Murata-Kamiya, N., Kurashima, Y., Teishikata, Y., Yamahashi, Y., Saito, Y., Higashi, H., Aburatani, H., Akiyama, T., Peek, R. M., Jr., Azuma, T., and Hatakeyama, M. (2007) *Oncogene* **26,** 4617–4626
- 18. Kurashima, Y., Murata-Kamiya, N., Kikuchi, K., Higashi, H., Azuma, T., Kondo, S., and Hatakeyama, M. (2008) *Int. J. Cancer.* **122,** 823–831
- 19. Lu, H., Wu, J. Y., Kudo, T., Ohno, T., Graham, D. Y., and Yamaoka, Y. (2005) *Mol. Biol. Cell* **16,** 4954–4966
- 20. Grimes, C. A., and Jope, R. S. (2001) *Prog. Neurobiol.* **65,** 391–426
- 21. Romashkova, J. A., and Makarov, S. S. (1999) *Nature* **401,** 86–90
- 22. Szabò, I., Brutsche, S., Tombola, F., Moschioni, M., Satin, B., Telford, J. L., Rappuoli, R., Montecucco, C., Papini, E., and Zoratti, M. (1999) *EMBO J.* **18,** 5517–5527
- 23. Papini, E., Bugnoli, M., De Bernard, M., Figura, N., Rappuoli, R., and Montecucco, C. (1993) *Mol. Microbiol.* **7,** 323–327
- 24. Ricci, V., Galmiche, A., Doye, A., Necchi, V., Solcia, E., and Boquet, P. (2000) *Mol. Biol. Cell* **11,** 3897–3909
- 25. Galceran, J., Hsu, S. C., and Grosschedl, R. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98,** 8668–8673
- 26. Hovanes, K., Li, T. W., Munguia, J. E., Truong, T., Milovanovic, T., Lawrence Marsh, J., Holcombe, R. F., and Waterman, M. L. (2001) *Nat. Genet.* **28,** 53–57
- 27. Salic, A., Lee, E., Mayer, L., and Kirschner, M. W. (2000) *Mol. Cell.* **5,** 523–532
- 28. Moon, R. T., Bowerman, B., Boutros, M., and Perrimon, N. (2002) *Science* **296,** 1644–1646
- 29. Yum, H. K., Arcaroli, J., Kupfner, J., Shenkar, R., Penninger, J. M., Sasaki, T., Yang, K. Y., Park, J. S., and Abraham, E. (2001) *J. Immunol.* **167,** 6601–6608
- 30. Li, Y., Wandinger-Ness, A., Goldenring, J. R., and Cover, T. L. (2004) *Mol. Biol. Cell* **15,** 1946–1959
- 31. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000) *Nature* **406,** 86–90
- 32. Takemaru, K., Yamaguchi, S., Lee, Y. S., Zhang, Y., Carthew, R. W., and Moon, R. T. (2003) *Nature* **422,** 905–909
- 33. Szabó, I. L., Pai, R., Jones, M. K., Ehring, G. R., Kawanaka, H., and Tarnawski, A. S. (2002) *Exp. Biol. Med.* **227,** 412–424
- 34. Doucas, H., Garcea, G., Neal, C. P., Manson, M. M., and Berry, D. P. (2005) *Eur. J. Cancer.* **41,** 365–379
- 35. Clements, W. M., Wang, J., Sarnaik, A., Kim, O. J., MacDonald, J., Fenoglio-Preiser, C., Groden, J., and Lowy, A. M. (2002) *Cancer Res.* **62,** 3503–3506
- 36. Oshima, H., Matsunaga, A., Fujimura, T., Tsukamoto, T., Taketo, M. M., and Oshima, M. (2006) *Gastroenterology* **131,** 1086–1095

